Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a first‐in‐human study and during experimental human endotoxaemia in healthy subjects

Christopher Geven(Radboud University Nijmegen), Peter Pickkers(Radboud University Nijmegen), Dirk van Lier(Radboud University Nijmegen), Alice Blet(Inserm), Matthijs Kox(Radboud University Medical Center), Alexandre Mebazaa(Marqueurs cardiovasculaires en situation de stress), Bas ten Elzen(Radboud University Nijmegen), Roel V. Peelen(Radboud University Nijmegen)
British Journal of Clinical Pharmacology
June 1, 2018
Cited by 44


Related Papers